磷酸化蛋白质组学界定肝细胞癌亚型并确定治疗靶点
该研究对肝细胞癌临床队列进行高覆盖磷酸化蛋白质组学分析,将肝细胞癌分为A、B、C三个恶性程度递增的亚型,并与患者预后、肿瘤分期、血清甲胎蛋白水平、癌栓和肿瘤大小相关。C亚型激酶活性失调最显著,药物博舒替尼在肝癌细胞系和患者来源异种移植小鼠模型中抑制C亚型肿瘤生长。
要点
- 磷酸化蛋白质组学将肝细胞癌分为A、B、C三个亚型,恶性程度依次递增。
- 亚型与患者预后、肿瘤分期、血清甲胎蛋白水平、癌栓和肿瘤大小相关。
- 博舒替尼在肝癌细胞系和患者来源异种移植小鼠模型中抑制C亚型肿瘤生长。
核心结论
- 研究全面探索了肝细胞癌的磷酸化蛋白质组学景观,建立了与临床特征匹配的新亚型,并为恶性程度最高的C亚型确定了潜在治疗靶点。
研究设计与样本
- 对肝细胞癌临床队列进行高覆盖磷酸化蛋白质组学分析,并使用肝癌细胞系和对应磷酸化蛋白质组学亚型的肝细胞癌患者来源异种移植小鼠模型验证有效治疗靶点。
主要发现
- 磷酸化蛋白质组学分析将肝细胞癌分为A、B、C三个亚型,恶性程度依次递增。
- 亚型与临床特征相关,包括患者预后、肿瘤分期、血清甲胎蛋白水平、癌栓和肿瘤大小。
- 从不同磷酸化蛋白质组学亚型推断的肝细胞癌失调激酶活性谱一致识别出与细胞增殖相关的激酶活性增加。
- C亚型肝细胞癌患者激酶活性失调最显著,提示潜在治疗靶点。
- 药物博舒替尼在肝癌细胞系和代表磷酸化蛋白质组学亚型的肝细胞癌患者来源异种移植小鼠模型中抑制C亚型肿瘤生长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Only a minority of patients could benefit from systemic therapy owing to the high heterogeneity of HCC. Therefore, a deeper understanding of the pathogenesis of HCC is essential for precision therapy. Genomic and proteomic studies of HCC have enhanced our understanding of HCC. However, the phosphoproteomic characterization of HCC remains poorly understood. APPROACH AND RESULTS: We conducted an in-depth analysis of a clinical cohort of HCC using high-coverage phosphoproteomic. Effective therapeutic targets were validated using liver cancer cell lines and HCC patient-derived xenograft mouse models that correspond to the phosphoproteomic subtypes of HCC. Phosphoproteomic analysis classified HCC into 3 subtypes, A, B, and C, with increasing malignancy and correlation with clinical features, including patient prognosis, tumor staging, serum alpha-fetoprotein levels, tumor thrombus, and tumor size. Phosphoproteomic subtyping deeply reflected the biological characteristics and clinical features of patients with HCC. The profiles of HCC-dysregulated kinase activities inferred from the different phosphoproteomic subtypes consistently identify increased kinase activity related to cell proliferation. Subtype-C HCC patients showed the most significant dysregulation, indicating a potential therapeutic target. The corresponding drug, bosutinib, demonstrated efficacy in inhibiting the growth of subtype C tumors in liver cancer cell lines and HCC patient-derived xenograft mouse models representative of the phosphoproteomic HCC subtypes. CONCLUSIONS: Our study provides a comprehensive exploration of the phosphoproteomic landscape of HCC, establishing new subtypes that match clinical features and identifying potential therapeutic targets for the most malignant C subtype.
引用
- Zhang Z, Zhang Z, Zhang Y, et al. Phosphoproteomics delineates hepatocellular carcinoma subtypes and pinpoints therapeutic targets. Hepatology. 2025. PMID: 39887258. doi:10.1097/HEP.0000000000001250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。